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Abstract A new aspartic proteinase from the human malaria
parasite Plasmodium falciparum is able to hydrolyse human
haemoglobin at a site known to be the essential primary
cleavage site in the haemoglobin degradation pathway. Thus,
plasmepsin IV may play a crucial role in this critical process
which yields nutrients for parasite growth. Furthermore,
synthetic inhibitors known to inhibit parasite growth in red
cells in culture are able to inhibit the activity of this enzyme in
vitro. As a result, plasmepsin IV appears to be a potential target
for the development of new antiparasitic drugs. ß 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
In its intra-erythrocytic stages, the human malaria parasite,
Plasmodium falciparum, degrades up to 80% of the haemoglo-
bin in the infected red blood cell in order to provide nutrients
for parasite growth and development [1,2]. This process,
which occurs within the parasite digestive vacuole, is mediated
by aspartic, cysteine and metallo proteinases, and blockade by
inhibitors of these enzymes results in parasite death [3,4].
Current evidence suggests that aspartic proteinases may be
responsible for initiating this haemoglobin degradation path-
way [5] and two such enzymes, plasmepsins I and II, have
been identi¢ed within the digestive vacuole [2] and character-
ised [6]. Crystal structures have been solved for plasmepsin II
in its mature enzyme form [7] and a truncated form of the
zymogen, proplasmepsin II [8]. We have recently reported [9]
that as many as nine aspartic proteinases can be identi¢ed
within the sequences that have accumulated in the databases
as a result of the P. falciparum genome project. Full-length
cDNA sequences of two of the putative new enzymes (pro-
plasmepsins IV and VI) were detailed previously [10] and it
appears that plasmepsin IV is also present within the digestive
vacuole of the P. falciparum parasite (Roland Cooper, person-
al communication). The mature enzyme, plasmepsin IV,
shares approximately 70% amino acid identity [10] with the
previously described plasmepsins I and II. In the present re-
port, we describe the production of proplasmepsin IV in re-
combinant form and detail for the ¢rst time the interaction of
the new mature enzyme, plasmepsin IV, with substrates and
inhibitors.
2. Materials and methods
The gene encoding a truncated form of proplasmepsin IV (begin-
ning at residue Thr74 of this precursor [10]) was ampli¢ed from P.
falciparum strain IT04 DNA by the polymerase chain reaction (PCR)
using Advantaq DNA polymerase (Clontech, Basingstoke, UK) and
forward (GGATCCCACAAAACACACAACTATAGG) and reverse
(GGATCCTTATAAATTTTTAGCTAGCTACTGCAAAAC) prim-
ers which contained BamHI sites (in italics) at their respective 5P-
ends. The conditions used were: 95‡C for 5 min followed by 20 cycles
of: 95‡C for 1 min; 60‡C for 1 min; 72‡C for 1 min; prior to a ¢nal
elongation step of 72‡C for 5 min. The resultant 1145 bp product was
ligated into the pGEM-T vector (Promega, Southampton, UK) and
sequenced using an Applied Biosystems ABI 3100 capillary DNA
sequencer. The DNA insert was excised with BamHI, cloned into
the expression vector pET3b and a clone with the DNA in the correct
orientation and reading frame was selected after sequencing. The
pET3b construct was transformed into Escherichia coli strain
BL21DE3pLysS and induction, puri¢cation and refolding of the re-
sultant insoluble recombinant proplasmepsin IV were performed as
described previously for proplasmepsin II [11]. Autoactivation of pro-
plasmepsin IV was accomplished by the addition of one tenth volume
of 1 M sodium acetate bu¡er pH 4.7 (the ionic strength of which had
been adjusted to 1 M by the addition of NaCl), followed by incuba-
tion at 37‡C for 30 min. The resultant protein was resolved by SDS^
PAGE and blotted onto polyvinylidene di£uoride membrane. N-ter-
minal sequencing by automated Edman degradation was performed
by Alta Bioscience (Birmingham, UK).
The hydrolysis of chromogenic peptide substrates at pH 4.7 was
monitored spectrophotometrically as described previously [4,6]. The
derived kinetic constants Km and kcat always had estimated errors of
6 15%. The concentration of active enzyme used in each assay was
determined by active site titration with isovaleryl pepstatin as de-
scribed previously [12]. Ki values for inhibitor interactions with plas-
mepsins IV and II were determined at pH 4.7 as described previously
[12] using the chromogenic substrates Lys-Pro-Ile-Glu-Phe*Nph-Arg-
Leu and Lys-Glu-Phe-Ala-Phe*Nph-Ala-Leu-Lys respectively (where
* is the scissile peptide bond).
Human haemoglobin (Sigma, Poole, UK) was puri¢ed by size ex-
clusion chromatography on Sephadex G-50 resin (Pharmacia, Upp-
sala, Sweden) to remove contaminating peptides. Fractions were col-
lected and analysed for purity by SDS^PAGE. Puri¢ed haemoglobin
(12.5 Wg) was incubated with 250 ng pre-activated plasmepsin IV at
37‡C, pH 4.7 in a ¢nal digest volume of 100 Wl 0.1 M sodium acetate
bu¡er (0.1 M ionic strength) for varying times. Digestion was stopped
by the addition of SDS loading dye and boiling for 5 min prior to
analysis by SDS^PAGE on a 20% polyacrylamide gel.
Erythrocyte membrane extracts were prepared as follows. Fresh
human blood (20 ml, harvested into 1 mM EDTA as an anticoagu-
lant) was centrifuged at 3000Ug and the plasma, platelet and leuko-
cyte layers were removed by aspiration. The remaining packed cells
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were lysed in ¢ve volumes of lysis solution (5 mM Na2PO4, 5 mM
MgCl2) and centrifuged at 14 000Ug for 15 min. The resultant pellet
(containing mostly membranous material) was washed a further four
times in ¢ve volumes of bu¡er until no further haemolysis was evi-
dent. The pelleted membrane fraction was washed a further three
times in two volumes of 0.1% (w/v) saponin (Sigma, Poole, UK) by
centrifugation (14 000Ug) and resuspending prior to ¢nal resuspen-
sion in 3 ml of the same solution. Digests were performed as follows:
17 Wl of membrane extract was incubated with 10 Wl (0.5 Wg) of either
plasmepsin II or plasmepsin IV, over a range of pH values. The pH
was maintained by the addition of 10% (v/v) of the appropriate bu¡er,
(1 M sodium acetate pH 4.7; 1 M MES pH 5.5; or 1 M MOPS pH
6.6) in a ¢nal reaction volume of 1 ml. Samples were incubated for
16 h at 37‡C and the ¢nal pH value was con¢rmed at the end of each
digestion period using a standard laboratory pH probe. Digests were
individually concentrated in Microspin Concentrators (Amicon Inc.,
Beverley, MA, USA) to a ¢nal volume of 20 Wl, whereupon 5 Wl of
SDS loading bu¡er was added prior to analysis by SDS^PAGE on a
10.5% gel.
3. Results and discussion
The sequence of the proplasmepsin IV DNA ampli¢ed by
PCR as described in Section 2 was identical to that ¢rst re-
ported by Humphreys et al. [10] with the exception of an
AAA^AGA substitution in the codon for Lys179CArg.
The arginine codon was detected in three independent ampli-
¢cation reactions so that there would appear to be a natural
polymorphism in the basic residue encoded at position 179.
The DNA encoding the Arg179 variant was expressed in E.
coli as described in Section 2 and the resultant recombinant
proplasmepsin IV was solubilised and refolded using the same
protocols that were elucidated initially for recombinant
proplasmepsin II [11]. To con¢rm the identity of the
44 kDa proplasmepsin IV, N-terminal sequencing was
performed and gave the sequence XXXTGGQQMGRDP
(where the identity of amino acid X could not be determined).
The pET3b vector encodes the sequence MASMTGGQQM-
GRDP, so that the recombinant protein was coincident at its
N-terminus with that of this N-terminal leader peptide pro-
vided by the vector (but lacking the initiator methionine).
Incubation of the 44 kDa proplasmepsin IV at pH 4.7 resulted
in its conversion to a protein which migrated on SDS^PAGE
with an apparent molecular weight of 38 kDa (data not
shown). This conversion was inhibited by inclusion of pepsta-
tin. N-terminal analysis of the 38 kDa band gave two over-
lapping sequences FKSGYA and KSGYAQ, indicating that
autoactivation had taken place at two adjacent residues
(marked by s) in the following sequence:
b Proplasmepsin IV VK E S F K FsFsK S G Y A QV
b Proplasmepsin I VK E S L K F F K T G L T QV
b Proplasmepsin II VK E S V N FuL N S G L T KV
Thus, the autoactivation appears to have taken place at a
comparable site in the propart of proplasmepsin IV to that
previously observed for proplasmepsin II [6], as indicated
above. However, the sequence of the propart of proplasmep-
sin IV in this region is closely similar to that of proplasmepsin
I (see above). Despite extensive e¡orts previously reported [4],
recombinant proplasmepsin I was found to be incapable of
undergoing autoactivation. Since plasmepsin IV clearly can
cleave within the VSer-(Phe/Leu)-Lys-Phe-Phe-Lys-(Ser/
Thr)-GlyV sequence, it may be possible that plasmepsin IV
initiates cleavage of the proplasmepsin I precursor. Proteomic
analysis of the digestive vacuole (Roland Cooper, personal
communication) has indicated that plasmepsin IV is a constit-
uent of the parasite digestive vacuole, along with plasmepsin I
(and plasmepsin II [2]).
The activity of recombinant plasmepsin IV against native
human haemoglobin was investigated. At pH 4.7, the enzyme
was able to degrade haemoglobin so that no bands remained
visible on SDS^PAGE (results not shown). When an excess of
haemoglobin was used as substrate in a 5 min incubation, a
major early intermediate in the degradation was observed at
approximately 14 kDa (Fig. 1). N-terminal analysis of this
band revealed the sequence Leu-Ser-Phe-Pro-Thr consistent
with a cleavage of the K-globin chain at the Phe33^Leu34
bond in the hinge region of this molecule. This is precisely
the bond believed to be the primary cut site necessary to
initiate haemoglobin degradation in the parasite digestive vac-
uole and is the only cut site which plasmepsins I and II share
in common when human haemoglobin is used as substrate [2].
Thus, it appears that, in common with the other digestive
vacuole plasmepsins, plasmepsin IV may also have the poten-
tial to initiate the vacuolar haemoglobin digestion pathway.
In addition to haemoglobin, the spectrin associated with the
membrane of the host red blood cell is also depleted during
infection by Plasmodium parasites [13]. Membrane extracts
prepared from human erythrocytes as described in Section 2
displayed two prominent bands on SDS^PAGE that corre-
spond to the K- (260 kDa) and L- (225 kDa) chains of spectrin
(Fig. 2, lane 1). Incubation of the membrane extract with the
recombinant plasmepsin IV at pH 4.7 resulted in essentially
complete degradation of all visible bands on SDS^PAGE
Fig. 1. Degradation of haemoglobin by plasmepsin IV. Human hae-
moglobin (12.5 Wg) was incubated with recombinant plasmepsin IV
(250 ng) at 37‡C in 0.1 M sodium acetate bu¡er pH 4.7 for the fol-
lowing times: lane 1, 0 min; lane 2, 5 min; lane 3, 15 min; lane 4,
30 min; lane 5, 60 min; lane 6, 120 min; lane 7, 240 min; lane 8,
480 min. Incubation of substrate alone for 480 min resulted in no
change in the protein pro¢le of the sample (not shown).
Fig. 2. Digestion of erythrocyte membrane extract by recombinant
plasmepsins IV and II. Lane 1: erythrocyte membrane extract
alone; lanes 2, 4 and 6: membrane extract incubated with recombi-
nant plasmepsin IV at pH 4.7, 5.5 and 6.6 respectively; lanes 3, 5
and 7: membrane extract incubated with recombinant plasmepsin II
at pH 4.7, 5.5 and 6.6 respectively. Incubation of substrate alone
for 480 min resulted in no change in the protein pro¢le of the sam-
ple (not shown).
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(Fig. 2, lane 2). At pH 5.5, the extent of digestion was less
(Fig. 2, lane 4) even after an incubation period of 16 h. At pH
6.6, although proteolysis to generate intermediates of smaller
size was still occurring (Fig. 2, lane 6), the intermediates were,
in general, larger in turn than those that were detected at pH
5.5. Indeed, the pattern of spectrin digestion by plasmepsin II
at pH 6.6 (Fig. 2, lane 7) was comparable to that observed
with plasmepsin IV (lane 6). It has been suggested previously
that spectrin degradation in infected red blood cells does not
occur in the digestive vacuole but rather is accomplished at a
higher pH within the cytosol of the red cell and it was postu-
lated that this proteolysis might be accomplished by plasmep-
sin II which has been detected in the host cell cytosol [14].
Recent evidence suggesting local regions of acidi¢cation with-
in parasitised red cells may also prove consistent with plas-
mepsin II activity against spectrin [15] and, since plasmepsin
IV is also capable of spectrin degradation, it would appear
that it may also be a candidate in this process although its
existence outside the digestive vacuole is yet to be established.
The ability of recombinant plasmepsin IV to cleave several
synthetic peptide substrates was also examined. The kinetic
parameters obtained with each of four substrates (Table 1)
were similar (within a factor of 3^4-fold) to their counterpart
values reported previously for cleavage of each of these sub-
strates by recombinant plasmepsin II [6]. In this regard then,
the active sites of the two enzymes would appear to be com-
parable. Direct comparisons with plasmepsin I are more com-
plicated because of the di⁄culties in obtaining this enzyme in
an active recombinant form. Plasmepsin IV was potently in-
hibited by the acetyl, isovaleryl and isobutyryl variants of
pepstatin (Table 2). The shorter lactoyl-pepstatin, which has
a hydrophilic lactoyl substituent in P3 in place of the Val
residue of the other three variants of pepstatin, was a consid-
erably poorer inhibitor not only of plasmepsin IV but also of
plasmepsin II. In contrast, three chemically synthesised inhib-
itors which we have tested previously [4] as inhibitors of plas-
mepsin I and plasmepsin II (and the structures of which are
detailed in Moon et al. [4]) were found to be 16^80 times more
potent inhibitors of plasmepsin IV than plasmepsin II. These
compounds thus permit discrimination between the active
sites of plasmepsin IV and plasmepsin II where the synthetic
peptide substrates do not. The potencies of Ro40-4388 and
Ro40-5576 towards plasmepsin IV (Table 2) are closely sim-
ilar to those reported previously [6] for plasmepsin I. Plasmep-
sin IV is the most sensitive of the digestive vacuole enzymes to
Ro42-1118, which is 6-fold and 80-fold more potent against
plasmepsin IV than plasmepsins I and II respectively. Since
this compound is also an inhibitor of P. falciparum growth in
red blood cells in culture [4], this may suggest plasmepsin IV
as a possible target for the action of this compound in the
parasite.
From the above analyses, it is clear that plasmepsin IV has
an active site that is similar to, but yet distinct from those of
plasmepsin I and plasmepsin II so that the three enzymes
might well act in concert in the digestive vacuole of P. falci-
parum feeding within the con¢nes of the red blood cell. While
this might suggest that inhibition of individual enzymes might
be insu⁄cient to kill the parasite, the broad similarities be-
tween the digestive vacuole plasmepsins may permit the devel-
opment of compounds able to inhibit all three enzymes to
produce a drug capable of imposing a multiple blockade on
the pathway of haemoglobin digestion.
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